Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. The post ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition appeared first on Pharmaceutical Technology.

HR 162

HR Marketing Hormones FDA Approval 162

pharmaphorum

AUGUST 1, 2024

Bayer files elinzanetant as a non-hormonal treatment for menopausal symptoms, with Astellas' first-to-market Veozah in its sights

Hormones 115

Hormones Drugs Marketing 115

Pharmaceutical Technology

AUGUST 8, 2022

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

FEBRUARY 24, 2023

It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

Pharmaceutical Technology

SEPTEMBER 8, 2022

Increasing drug failure rates and essential drug shortages have driven the growth of the compounding pharmacies market, which has a high growth potential, especially in emerging economies. Discover the top pharmaceutical compounding companies in contract marketing. Excipients. Active pharmaceutical ingredients (APIs). Packaging. •

Marketing 100

Marketing Pharmacy Containment Sales 100

pharmaphorum

MARCH 19, 2024

New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah

Hormones 109

Hormones Drugs Marketing 109

BioTech 365

FEBRUARY 22, 2021

Global Hormonal Replacement Therapy (HRT) Drugs Market Report 2020-2030 – ResearchAndMarkets.com Global Hormonal Replacement Therapy (HRT) Drugs Market Report 2020-2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Drugs For Hormonal Replacement Therapy Global Market Report 2020-30: COVID-19 Impact and Recovery” (..)

Hormones 40

Hormones Marketing Drugs 40

XTalks

NOVEMBER 6, 2024

per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. With an expanding patent portfolio and partnerships in human and animal health, Gelteq promotes therapeutic efficacy and patient adherence across diverse health markets.

Drug Delivery 104

Drug Delivery Drugs Bioequivalency Bioavailability 104

XTalks

MARCH 19, 2025

Eneboparatide (AZP-3601), an investigational parathyroid hormone 1 receptor (PTH1R) agonist, met its primary endpoint in the CALYPSO Phase III trial, offering new data for adults with chronic hypoparathyroidism. AstraZeneca received eneboparatide during its $1.05 Without proper PTH function, patients may face kidney and bone complications.

Trials 59

Trials Hormones Engineer Licensing 59

BioPharma Reporter

SEPTEMBER 19, 2024

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) stage two or three early breast cancer, who are at high risk of cancer recurrence.

FDA Approval 93

FDA Approval HR Hormones Marketing 93

BioTech 365

NOVEMBER 15, 2021

Theramex Enters OTC Market with Femarelle®, a Non-hormonal Option to Treat Menopause Symptoms Theramex Enters OTC Market with Femarelle®, a Non-hormonal Option to Treat Menopause Symptoms The Theramex portfolio now includes a safe and effective non-hormonal option to treat menopause … Continue reading →

Hormones 40

Hormones Marketing 40

XTalks

SEPTEMBER 13, 2024

This blog explores the top 10 largest publicly traded healthcare companies by market capitalization , making strides in healthcare delivery and innovation. UnitedHealth Group (UNH) Market Capitalization : $738.67 Elevance Health (ELV) Market Capitalization : $170.91 HCA Healthcare (HCA) Market Capitalization : $136.05

Marketing 98

Marketing Pharmacy Gene Therapy Hormones 98

BioTech 365

DECEMBER 21, 2021

Biosimilar Hormones Global Market Research Report 2021: Breakdown by Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars – ResearchAndMarkets.com Biosimilar Hormones Global Market Research Report 2021: Breakdown by Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin (..)

Hormones 40

Hormones Insulin Marketing Research 40

XTalks

FEBRUARY 5, 2025

a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 Metsera, Inc., per share, raising $275 million in gross proceeds. billion in 2024 to $37.94

Hormones 59

Hormones Bioavailability Clinical Trials Clinical Trials 59

Delveinsight

SEPTEMBER 27, 2021

However, it has been observed that even after early therapy administration, relapse risk is substantial, and the most effective therapies pose a considerable risk with long-term administration, creating a huge unmet need for the market. The West syndrome market has different forms of ACTH available for infantile spasms.

Marketing 77

Marketing Hormones Radiology Pharma Companies 77

BioTech 365

APRIL 26, 2021

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & (..)

Generic Drugs 40

Generic Drugs Dermatology Hormones Marketing 40

pharmaphorum

MAY 27, 2021

The two companies share marketing rights to relugolix products in North America, while Pfizer has exclusive rights elsewhere. Combining it with the hormonal drugs reduces side effects – such as bone loss – that can result from reducing oestrogen levels.

Hormones 98

Hormones Sales Marketing Drugs 98

pharmaphorum

MAY 20, 2021

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. Hormone relapsed disease has stopped responding to hormone therapy and is usually treated with ADT alone or with Bayer’s Nubeqa (darolutamide) and ADT.

Hormones 98

Hormones Drugs Trials Manufacturing 98

The Pharma Data

JUNE 12, 2022

Investigational phase 3 data for Sogroya ® ( somapacitan ) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress 1. Based on the results of the REAL 4 study, there is potential for a once-weekly option for children with growth hormone deficiency.”. cm/year, compared to 11.7

Hormones 52

Hormones Medicine Trials Production 52

pharmaphorum

SEPTEMBER 8, 2021

NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug. ” The post NICE changes its mind on J&J’s Erleada in prostate cancer appeared first on.

Hormones 98

Hormones Drugs Trials Marketing 98

XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. And when it comes to weight loss, change is good, it ends off saying.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105

Hormones Antibody Trials Production 105

BioTech 365

JULY 16, 2021

Global Non-hormonal Therapies for Women’s Health Markets, 2021-2030: Target Indication, Type of Molecule, Purpose of Therapy, Mechanism of Action, Route of Administration, and Key Geographical Regions – ResearchAndMarkets.com Global Non-hormonal Therapies for Women’s Health Markets, 2021-2030: Target Indication, Type of … Continue (..)

Hormones 40

Hormones Marketing 40

STAT News

OCTOBER 25, 2022

The antitrust regulator in Spain has fined Merck approximately $39 million for preventing a competitor from marketing a generic version of a hormonal contraceptive, the latest effort by a European government to crack down on anti-competitive practices in the pharmaceutical industry.

Regulation 98

Regulation Hormones Manufacturing Production 98

XTalks

NOVEMBER 21, 2024

Additionally, over a 176-week period, weekly injections of tirzepatide (marketed as Zepbound and Mounjaro) using pooled doses of 5 mg, 10 mg and 15 mg, significantly reduced the risk of disease progression to type 2 diabetes by 94 percent compared with placebo in adult prediabetes patients who were obese or overweight.

Sales 105

Sales Insulin Drugs Trials 105

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. Though as we anticipated, we believe it will likely be relegated to later-line, post-biologics setting given lesser efficacy and safety baggage.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

STAT News

MARCH 21, 2023

A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up on other popular drugs on the market.

Hormones 98

Hormones Drugs Clinical Trials Clinical Trials 98

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours.

Sales 98

Sales Drugs Hormones Pharma Production 98

pharmaphorum

MARCH 23, 2021

The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales predicted for the drug if it makes it to market. The five-year survival rate for patients with mCRPC is approximately 15%.

Trials 124

Trials Hormones Sales Drugs 124

Fierce Pharma

SEPTEMBER 6, 2023

Royalty Pharma, a company known for ponying up chunks of cash in exchange for long-term drug royalties, has hopped on board with Ascendis Pharma's long-acting growth hormone Skytrofa. Ascendis hopes to bring its second TransCon product to the market and overcome manufacturing issues.

Manufacturing 83

Manufacturing Hormones Drugs Production 83

Pharmaceutical Technology

FEBRUARY 28, 2023

Mayne Pharma’s portfolio to be acquired comprises around 45 commercial products, four pipeline products and 40 approved, non-marketed products. It also includes several generic products focused on women’s health, a cardiovascular product, a hormonal vaginal ring, and a birth control pill.

Production 130

Production Hormones Marketing Medicine 130

Pharmaceutical Technology

APRIL 14, 2023

The company is expecting regulatory decisions for the drug in additional markets across the world this year. In March 2023, Eli Lilly secured expanded approval from the FDA for Verzenio (abemaciclib) to treat breast cancer patients.

Manufacturing 130

Manufacturing Drugs Hormones Packaging 130

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

pharmaphorum

AUGUST 11, 2020

Bayer will pay $425 million up front and potential milestone payments of up to $450 million until launch, followed by potential undisclosed “triple digit million” milestone payments once the drug is on the market. The deal is expected to close next month, subject to customary conditions such as anti-trust approval.

Drugs 98

Drugs Hormones Marketing Trials 98

BioTech 365

AUGUST 24, 2021

Global Gynecology Drugs Market Research Report 2021-2026 – ResearchAndMarkets.com Global Gynecology Drugs Market Research Report 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Gynecology Drugs Market, By Therapeutics (Hormonal Therapy vs. Non-Hormonal Therapy), By Indication, By Distribution Channel, (..)

Marketing 40

Marketing Hormones Research Drugs 40

pharmaphorum

MARCH 8, 2021

The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies abiraterone and enzalutamide but have relapsed.

Hormones 98

Hormones Marketing Trials DNA 98

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. billion in 2021 to $61.6 billion by 2030.

Insulin 98

Insulin Hormones FDA Approval Sales 98